Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Drug Shortages Don't Lack For Attention; Sec. Sebelius Meets With Stakeholders

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA will soon release a report on the drug shortage problem and recommendations with respect to its role.

You may also be interested in...



Drug Shortages: FDA Wants Advanced Warning; Practitioners Want Even More

Presenters at drug shortage workshop want estimates of the scope and severity of a pending supply interruption to obtain alternative therapies.

Drug Shortages: FDA Wants Advanced Warning; Practitioners Want Even More

Presenters at drug shortage workshop want estimates of the scope and severity of a pending supply interruption to obtain alternative therapies.

Rx Shortages Defy Easy Solutions, FDA Notes As It Offers Congress Some Ideas

FDA takes a variety of approaches as it tackles the problem of drug shortages and is tying the high-profile issue to related priorities.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS072755

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel